complex issue that needs further evaluation to determine the risk of these agents in individual patients. Understanding the mechanism behind the cardiovascular effects is also critical to assist in patient selection and evaluation of an individual's risk versus benefit. While many have attempted to present the mechanism simplistically, two possible mechanisms, as reviewed below, have garnered the most attention to date.
Mechanistic Considerations
Selective COX-2 inhibitors were developed to minimize GI toxicity that occurs with inhibition of COX-1 expression in the GI tract. Two major studies were conducted to evaluate the differences in GI toxicity between traditional NSAIDS and COX-2 inhibitors. The Celecoxib Longterm Arthritis Safety Study (CLASS) showed a non-significant reduction in upper GI complications and a significant reduction in upper GI complication when combined with symptomatic ulcers compared with ibuprofen and diclofenac [Silverstein et al. 2000] . There was no difference in the rate of myocardial infarction (MI) in patients taking celecoxib in this study, but the study was not designed to evaluate this risk and patients were at low risk for cardiovascular events. Conversely, in the Vioxx Gastrointestinal Outcomes Research (VIGOR) an increased incidence in MIs was found along with a decrease in gastrointestinal events [Bombardier et al. 2000] . The difference in selectivity for the COX-2 isoenzyme that was supposed to decrease GI toxicity has now been associated with the potential risk of adverse cardiovascular effects with the COX-2 inhibitors.
While many theories are well-described and well-researched, the mechanism of the cardiovascular effects still remains virtually unknown and controversial. The two most commonly accepted theories for the cardiovascular consequences of selective COX-2 inhibition include a shift in the pro-thrombotic/anti-thrombotic balance with COX-2-mediated prostacyclin and COX-1 dependent-thromboxane and an imbalance between vasoconstrictive and vasodilatory prostaglandins.
Prostaglandins are generated by metabolism of arachidonic acid by cyclooxygenase (COX) and prostaglandin synthase enzymes. There are 2 major COX isoenzymes with differing effects and locations. COX-1 is expressed in many tissues, including the GI tract, kidneys, vascular wall, and platelets [Morita, 2002; Grosser et al. 2006] . The COX-1 isoenzyme produces prostaglandins and mediates production of thromboxane (Tx) A2, which promotes vasoconstriction and platelet aggregation. It is also responsible for protection (effects) of the gastric mucosa and regulating renal blood flow and platelet function. The COX-2 isoenzyme, undetectable in most tissues, is induced primarily at the site of inflammation. COX-2 is primarily responsible for producing prostaglandins in response to inflammation. Differences in the effects of traditional NSAIDS and COX-2 inhibitors are thought to be a result of the selectivity for COX-2 vs COX-1 isoenzyme.
The first hypothesis to explain the potential cardiovascular effects involves the balance of the COX-2 derived prostacyclin (PGI 2 ) and Tx A 2 , both of which play a role in vascular homeostasis [Weber 2004 ]. Prostacyclin and Tx A 2 are generated by the effects of COX isoenzymes on arachidonic acid [FitzGerald and Patrona, 2001 ]. Thromboxane A 2 , which promotes platelet aggregation, is synthesized by platelet and vascular smooth-muscle cells which express only the COX-1 isoenzyme. Conversely, prostacyclin, which inhibits thrombosis, is produced by the COX-2 isoenzyme. Non-selective inhibition with aspirin, for example, is effective for reducing thrombosis because it blocks the aggregation of platelets caused by Tx A 2 through a direct effect on the COX-1 isoenzyme. Selective inhibition of COX-2 reduces the antithrombotic effects of prostacyclin, while not inhibiting the detrimental effects of Tx A2. Unopposed COX-2 blockade may cause a negative thrombotic balance that could lead to a pro-thrombotic effect.
Information from clinical trials seems to support this phenomenon. The VIGOR trial reported a fivefold increase in MI with rofecoxib versus naproxen [Bombardier et al. 2000] . Note that this difference may have been in part because high dose naproxen is thought to inhibit platelet aggregation. Two placebo-controlled trials, Adenomatous Polyp PRevention on Vioxx (APPROVe) using rofecoxib and Adenoma Prevention with Celecoxib (APC) with celecoxib also showed an increased risk of cardiovascular events Bresalier et al. 2005] . However, if this negative thrombotic balance were solely responsible, then low-dose aspirin should negate this effect. In the APPROVe trial, low dose aspirin did not alter the risk associated with rofecoxib . Also, some comparative trials with COX-2 inhibitors and NSAIDS did not show a significant increase in CV risk [Solomon et al. 2005] . While the thrombotic balance may play a role, other factors must also be considered in the evaluating the cardiovascular safety of COX-2 inhibitors.
Another possible explanation for the increase in cardiovascular risk is the effect of prostaglandins on vasoconstriction and vasodilatation. COX-1 mediated TX 2 A2 is a vasoconstrictor, but COX-2 induced prostacyclin is a vasodilator. Clinically, both NSAIDS and COX-2 inhibitors have been reported to increase blood pressure. This increase in blood pressure may be due to increased salt retention, but also could be due to the imbalance in vasoconstrictor and vasodilator properties of COX-1 and COX-2 [Farkouh et al. 2007] . These effects have not been consistent among studies with some showing increases in systolic blood pressure of about 3-4 mm Hg and others showing no effect [Schwartz et al. 2002; Catella-Lawson et al. 1999] . In the APPROVe study, the rofecoxib group showed an increase in systolic blood pressure of 3.4 mm Hg compared with a decrease of 0.5 mm Hg in the placebo group. It remains questionable whether this modest increase in blood pressure could play a role in cardiovascular effects. A meta-analysis of 61 studies showed that a decrease of 2 mm Hg systolic blood pressure can decrease ischemic heart disease mortality and stroke [White et al. 2002] . Studies have also shown that small differences in blood pressure may affect outcomes including stroke in antihypertensive trials [Lewington et al. 2002] .
Following the withdrawal of rofecoxib and valdecoxib, the safety of nonselective NSAIDS has become an important question. Randomized, placebo-controlled trials addressing the cardiovascular safety of NSAIDS are not available. The safety of current NSAIDS is based on observational studies and COX-2 inhibitor trials with nonselective NSAIDS as a comparator. We must also consider that variability among NSAIDS may affect conclusions with regard to the safety of these agents as well as to the comparative efficacy of COX-2 inhibitors. For example, some studies have suggested that naproxen may be protective, while others have shown neutral effects [Rahme et al. 2002; Ray et al. 2002; Solomon et al. 2002; Mamdani et al. 2003 ] A meta-analysis evaluated COX-2 inhibitors and NSAIDS on the risk of vascular events. The authors concluded that high dose regimens of ibuprofen and diclofenac caused an increase in cardiovascular event when compared with placebo [Kearney et al. 2006] .
The exact mechanism for the cardiovascular events with COX-2 inhibitors is a complex issue and may be due to several factors. As a result, it is important to evaluate the literature critically to best determine patients who may benefit from these agents and patients who may be at risk. In addition to evaluating the risk of individual agents, the risk associated with drug exposure is also important. Factors to consider when individualizing therapy should include drug dose, length of therapy and risk for cardiovascular and gastrointestinal disease. The identification of an exact mechanism for the CV events related to COXIBS warrants further investigation along with answering several other key questions including whether or not all NSAIDS carry a cardiovascular risk, whether low-dose aspirin can decrease the risk, and what patients may be at risk or would benefit from currently marketed COX-2 inhibitors.
